The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
Open accessAbstract
Alzheimer's disease (AD) is the most common form of dementia among the elderly. In AD patients, memory loss is accompanied by the formation of beta-amyloid plaques and the appearance of tau in a pathological form. Given the lack of effective treatments for AD, the development of new management strategies for these patients is critical. The continued failure to find effective therapies using molecules aimed at addressing the anti-beta amyloid pathology has led researchers to focus on other non-amyloid-based approaches to restore memory function. Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compound found to effectively restore cognitive deficits in animal models of AD. More recently, PDE5 inhibitors have also been shown to effectively restore memory function. Accordingly, inhibitors of other members of the PDE family may also improve memory performance in AD and non-AD animal models. Hence, in this review, we will summarize the data supporting the use of PDE inhibitors as cognitive enhancers and we will discuss the possible mechanisms of action underlying these effects. We shall also adopt a medicinal chemistry perspective that leads us to propose the most promising PDE candidates on the basis of inhibitor selectivity, brain distribution, and mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Abel, T., Nguyen, P. V., Barad, M., Deuel, T. A. S., Kandel, E. R., & Bourtchouladze, R. (1997) · Cell · doi:10.1016/s0092-8674(00)81904-2 · Cited by 1,217
Harrison, P. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1761-y · Cited by 693
Impey, S., Mark, M., Villacres, E. C., Poser, S., Chavkin, C., & Storm, D. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80120-8 · Cited by 593
Sakamoto, K., Karelina, K., & Obrietan, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07080.x · Cited by 543
Bernabeu, R., Bevilaqua, L., Ardenghi, P., Bromberg, E., Schmitz, P., Bianchin, M., Izquierdo, I., & Medina, J. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.7041 · Cited by 498
Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling
Conti, M., Richter, W., Mehats, C., Livera, G., Park, J.-Y., & Jin, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r200029200 · Cited by 481
Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues
Lakics, V., Karran, E. H., & Boess, F. G. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.004 · Cited by 463
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442
Emptage, N., Bliss, T. V. P., & Fine, A. (1999) · Neuron · doi:10.1016/s0896-6273(00)80683-2 · Cited by 436
Barad, M., Bourtchouladze, R., Winder, D. G., Golan, H., & Kandel, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.15020 · Cited by 431
Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus
Lu, Y.-F., Kandel, E. R., & Hawkins, R. D. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10250.1999 · Cited by 408
CREB and the formation of long-term memory
Yin, J. C., & Tully, T. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80082-1 · Cited by 399
Burgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjornsson, J. M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 397
Lione, L. A., Carter, R. J., Hunt, M. J., Bates, G. P., Morton, A. J., & Dunnett, S. B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10428.1999 · Cited by 384
Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
Soderling, S. H., Bayuga, S. J., & Beavo, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7071 · Cited by 374
Targeting the CREB pathway for memory enhancers
Tully, T., Bourtchouladze, R., Scott, R., & Tallman, J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1061 · Cited by 357
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
Clapper, J. R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti, A., Tontini, A., Sanchini, S., Sciolino, N. R., Spradley, J. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2632 · Cited by 346
Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase
Fisher, D. A., Smith, J. F., Pillar, J. S., Denis, S. H. S., & Cheng, J. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15559 · Cited by 341
PDE4 inhibitors: current status
Spina, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.307 · Cited by 340
Immunohistochemical localization of PDE10A in the rat brain
Seeger, T. F., Bartlett, B., Coskran, T. M., Culp, J. S., James, L. C., Krull, D. L., Lanfear, J., Ryan, A. M., Schmidt, C. J., Strick, C. A., et al. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02754-9 · Cited by 334
Puzzo, D., Staniszewski, A., Deng, S. X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D. W., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0864-09.2009 · Cited by 331
Boess, F. G., Hendrix, M., van der Staay, F.-J., Erb, C., Schreiber, R., van Staveren, W., de Vente, J., Prickaerts, J., Blokland, A., & Koenig, G. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.040 · Cited by 330
Bourtchouladze, R., Lidge, R., Catapano, R., Stanley, J., Gossweiler, S., Romashko, D., Scott, R., & Tully, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834280100 · Cited by 312
Tadalafil pharmacokinetics in healthy subjects
Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02553.x · Cited by 284
Schmidt, C. J., Chapin, D. S., Cianfrogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132910 · Cited by 284
Luks, A. M., McIntosh, S. E., Grissom, C. K., Auerbach, P. S., Rodway, G. W., Schoene, R. B., Zafren, K., & Hackett, P. H. (2010) · Wilderness & Environmental Medicine · doi:10.1016/j.wem.2010.03.002 · Cited by 274
Grauer, S. M., Pulito, V. L., Navarra, R. L., Kelly, M. P., Kelley, C., Graf, R., Langen, B., Logue, S., Brennan, J., Jiang, L., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155994 · Cited by 269
Selective phosphodiesterase inhibitors: a promising target for cognition enhancement
Reneerkens, O. A. H., Rutten, K., Steinbusch, H. W. M., Blokland, A., & Prickaerts, J. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1273-x · Cited by 266
Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm069 · Cited by 266
Potentiation of calcium- and caffeine-induced calcium release by cyclic ADP-ribose.
Lee, H. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54148-x · Cited by 256
Naatanen, R., Kujala, T., Kreegipuu, K., Carlson, S., Escera, C., Baldeweg, T., & Ponton, C. (2011) · Brain · doi:10.1093/brain/awr064 · Cited by 244
Gresser, U., & Gleiter, C. H. (2002) · PubMed · Cited by 234
Siuciak, J. A., McCarthy, S. A., Chapin, D. S., Fujiwara, R. A., James, L. C., Williams, R. D., Stock, J. L., McNeish, J. D., Strick, C. A., Menniti, F. S., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.01.012 · Cited by 231
Li, Y.-F., Cheng, Y.-F., Huang, Y., Conti, M., Wilson, S. P., O'Donnell, J. M., & Zhang, H.-T. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5236-10.2011 · Cited by 231
Reversal of long-term dendritic spine alterations in Alzheimer disease models
Smith, D. L., Pozueta, J., Gong, B., Arancio, O., & Shelanski, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908706106 · Cited by 229
Pérez-Torres, S., Miró, X., Palacios, J. M., Cortés, R., Puigdoménech, P., & Mengod, G. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00097-1 · Cited by 229
Alford, S., Frenguelli, B. G., Schofield, J. G., & Collingridge, G. L. (1993) · The Journal of Physiology · doi:10.1113/jphysiol.1993.sp019838 · Cited by 221
Dysregulation of Protein Kinase A Signaling in the Aged Prefrontal Cortex
Ramos, B. P., Birnbaum, S. G., Lindenmayer, I., Newton, S. S., Duman, R. S., & Arnsten, A. F. T. (2003) · Neuron · doi:10.1016/s0896-6273(03)00694-9 · Cited by 218
Loughney, K., Hill, T. R., Florio, V. A., Uher, L., Rosman, G. J., Wolda, S. L., A. Jones, B., Howard, M. L., McAllister-Lucas, L. M., Sonnenburg, W. K., et al. (1998) · Gene · doi:10.1016/s0378-1119(98)00303-5 · Cited by 218
Cherry, J. A., & Davis, R. L. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990503)407:2<287::aid-cne9>3.0.co;2-r · Cited by 215
Cuadrado-Tejedor, M., Hervias, I., Ricobaraza, A., Puerta, E., Pérez-Roldán, J., García-Barroso, C., Franco, R., Aguirre, N., & García-Osta, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01517.x · Cited by 209
Self-citationIsolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase
Loughney, K., Snyder, P. B., Uher, L., Rosman, G. J., Ferguson, K., & Florio, V. A. (1999) · Gene · doi:10.1016/s0378-1119(99)00171-7 · Cited by 208
Verhoest, P. R., Chapin, D. S., Corman, M., Fonseca, K., Harms, J. F., Hou, X., Marr, E. S., Menniti, F. S., Nelson, F., O’Connor, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900521k · Cited by 205
PDE10A inhibition reverses subchronic PCP‐induced deficits in attentional set‐shifting in rats
Rodefer, J. S., Murphy, E. R., & Baxter, M. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03937.x · Cited by 199
Deshmukh, R., Sharma, V., Mehan, S., Sharma, N., & Bedi, K. L. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.027 · Cited by 194
Fujishige, K., Kotera, J., & Omori, K. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00963.x · Cited by 188
cGMP Regulated Protein Kinases (cGK)
Hofmann, F., Bernhard, D., Lukowski, R., & Weinmeister, P. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-68964-5_8 · Cited by 187
Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD
García-Barroso, C., Ricobaraza, A., Pascual-Lucas, M., Unceta, N., Rico, A. J., Goicolea, M. A., Sallés, J., Lanciego, J. L., Oyarzabal, J., Franco, R., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.052 · Cited by 184
Self-citationErceg, S., Monfort, P., Hernández‐Viadel, M., Rodrigo, R., Montoliu, C., & Felipo, V. (2005) · Hepatology · doi:10.1002/hep.20565 · Cited by 179
Rutten, K., Prickaerts, J., Hendrix, M., van der Staay, F. J., Şik, A., & Blokland, A. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.041 · Cited by 179
The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents
van der Staay, F. J., Rutten, K., Bärfacker, L., DeVry, J., Erb, C., Heckroth, H., Karthaus, D., Tersteegen, A., van Kampen, M., Blokland, A., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.005 · Cited by 177
Hebb, A. L. O., Robertson, H. A., & Denovan-Wright, E. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.11.009 · Cited by 172
cGMP Signalling in the Mammalian Brain: Role in Synaptic Plasticity and Behaviour
Kleppisch, T., & Feil, R. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-68964-5_24 · Cited by 161
In vivo, in vitro and in silico methods for small molecule transfer across the BBB
Mensch, J., Oyarzabal, J., Mackie, C., & Augustijns, P. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21745 · Cited by 160
Prickaerts, J., Steinbusch, H. W. M., Smits, J. F. M., & de Vente, J. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01301-0 · Cited by 156
van Staveren, W. C. G., Steinbusch, H. W. M., Ittersum, M. M., Repaske, D. R., Goy, M. F., Kotera, J., Omori, K., Beavo, J. A., & de Vente, J. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10955 · Cited by 155
Zhang, H. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00108-1 · Cited by 155
Phosphodiesterase type 5 inhibition improves early memory consolidation of object information
Prickaerts, J., Şık, A., van Staveren, W. C. G., Koopmans, G. C., Steinbusch, H. W. M., van der Staay, F. J., de Vente, J., & Blokland, A. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.022 · Cited by 154
Lü, Y.-F., & Hawkins, R. D. (2002) · Journal of Neurophysiology · doi:10.1152/jn.2002.88.3.1270 · Cited by 153
Hutson, P. H., Finger, E. N., Magliaro, B. C., Smith, S. M., Converso, A., Sanderson, P. E. J., Mullins, D. E., Hyde, L. A., Eschle, B. K., Turnbull, Z., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.009 · Cited by 146
Zhang, H., Zhao, Y., Huang, Y., Dorairaj, N. R., Chandler, L. J., & O’Donnell, J. M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300440 · Cited by 141
Prickaerts, J., Şık, A., van der Staay, F. J., de Vente, J., & Blokland, A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1967-7 · Cited by 138
GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses
Bruno, O., Fedele, E., Prickaerts, J., Parker, L. A., Canepa, E., Brullo, C., Cavallero, A., Gardella, E., Balbi, A., Domenicotti, C., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01524.x · Cited by 137
Zhang, H., & O’Donnell, J. M. (2000) · Psychopharmacology · doi:10.1007/s002130000414 · Cited by 136
Pérez-Torres, S., Cortés, R., Tolnay, M., Probst, A., Palacios, J. M., & Mengod, G. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00042-6 · Cited by 134
Sensitization of Calcium-induced Calcium Release by Cyclic ADP-ribose and Calmodulin
Lee, H. C., Aarhus, R., & Graeff, R. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.16.9060 · Cited by 134
Domek-Łopacińska, K., & Strosznajder, J. B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.108 · Cited by 133
Rutten, K., Prickaerts, J., & Blokland, A. (2005) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2005.09.002 · Cited by 132
PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
Robichaud, A., Savoie, C., Stamatiou, P. B., Tattersall, F. D., & Chan, C. C. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00142-8 · Cited by 131
Imanishi, T., Sawa, A., Ichimaru, Y., Miyashiro, M., Kato, S., Yamamoto, T., & Ueki, S. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00969-7 · Cited by 130
Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer's Disease
Domek-Łopacińska, K., & Strosznajder, J. B. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8104-x · Cited by 127
Rutten, K., Basile, J., Prickaerts, J., Blokland, A., & Vivian, J. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0999-1 · Cited by 125
Rutten, K., de Vente, J., Şık, A., Ittersum, M. M., Prickaerts, J., & Blokland, A. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.04.021 · Cited by 125
Phosphodiesterase Inhibitors for Cognitive Enhancement
Rose, G., Hopper, A. T., Vivo, M. D., & Tehim, A. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774370799 · Cited by 123
Assessing the emetic potential of PDE4 inhibitors in rats
Robichaud, A., Savoie, C., Stamatiou, P. B., Lachance, N., Jolicoeur, P., Rasori, R., & Chan, C. C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704457 · Cited by 120
Schultheiss, D., Müller, S., Nager, W., Stief, C. G., Schlote, N., Udo Jonas, A., Asvestis, C., Johannes, S., & Münte, T. (2001) · World Journal of Urology · doi:10.1007/pl00007092 · Cited by 119
Reyes-Irisarri, E., Ittersum, M. M., Mengod, G., & de Vente, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05589.x · Cited by 114
Bernabeu, R., Schröder, N., Quevedo, J., Cammarota, M., Izquierdo, I., & Medina, J. H. (1997) · Neuroreport · doi:10.1097/00001756-199707070-00026 · Cited by 111
Siuciak, J. A., McCarthy, S. A., Chapin, D. S., & Martin, A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-1014-6 · Cited by 111
Bolger, G. B., Rodgers, L., & Riggs, M. G. (1994) · Gene · doi:10.1016/0378-1119(94)90155-4 · Cited by 111
Phosphodiesterases in the Central Nervous System: Implications in Mood and Cognitive Disorders
Xu, Y., Zhang, H., & O’Donnell, J. M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_19 · Cited by 108
An, K., Hao, H., Zheng, X., Liang, Y. L., Xie, Y., Xie, T., Dai, C., Zhao, Q., Wu, X., Xie, L. Y., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-100 · Cited by 106
Cheng, Y., Wang, C., Lin, H.-B., Li, Y., Huang, Y., Xu, J., & Zhang, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1943-3 · Cited by 101
Miró, X., Pérez-Torres, S., Palacios, J. M., Puigdomènech, P., & Mengod, G. (2001) · Synapse · doi:10.1002/syn.1043 · Cited by 100
Gallo, E. F., & Iadecola, C. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0374-11.2011 · Cited by 98
Devan, B. D., SIERRAMERCADOJR, D., JIMENEZ, M., Bowker, J. L., Duffy, K. B., Spangler, E. L., & INGRAM, D. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.09.019 · Cited by 98
Cilostazol prevents amyloid β peptide25‐35‐induced memory impairment and oxidative stress in mice
Hiramatsu, M., Takiguchi, O., Nishiyama, A., & Mori, H. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01014.x · Cited by 96
Park, S. H., Kim, J. H., Bae, S. S., Hong, K. W., Lee, D., Leem, J. Y., Choi, B. T., & Shin, H. K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.068 · Cited by 96
Repaske, D. R., Corbin, J. G., Conti, M., & Goy, M. F. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90364-l · Cited by 96
Shimizu‐Albergine, M., Rybalkin, S. D., Rybalkina, I. G., Feil, R., Wolfsgruber, W., Hofmann, F. B., & Beavo, J. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-16-06452.2003 · Cited by 95
Kleiman, R. J., Kimmel, L. H., Bove, S. E., Lanz, T. A., Harms, J. F., Romegialli, A., Miller, K. S., Willis, A. D., Etages, S. D., Kuhn, M., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173294 · Cited by 94
Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum
Chalimoniuk, M., & Strosznajder, J. B. (1998) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815117 · Cited by 94
Hindmarch, I., Fuchs, H.-H., & Erzigkeit, H. (1991) · International Clinical Psychopharmacology · doi:10.1097/00004850-199100610-00005 · Cited by 94
Sakurai, H., Hanyu, H., Sato, T., Kume, K., Hirao, K., Kanetaka, H., & Iwamoto, T. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2012.00866.x · Cited by 91
Devan, B. D., Bowker, J. L., Duffy, K. B., Bharati, I. S., Jimenez, M. A., Sierra‐Mercado, D., Nelson, C. M., Spangler, E. L., & Ingram, D. K. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0232-z · Cited by 88
Kleiman, R. J., Chapin, D. S., Christoffersen, C. L., Freeman, J., Fonseca, K. R., Geoghegan, K. F., Grimwood, S., Guanowsky, V., Hajós, M., Harms, J. F., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.191353 · Cited by 87
Kelly, M. P., Logue, S. F., Brennan, J. A., Day, J. P., Lakkaraju, S., Jiang, L., Zhong, X., Tam, M., Rizzo, S. J. S., Platt, B. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000730107 · Cited by 85
Regulation of gene expression and its role in long-term memory and synaptic plasticity
Tully, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4239 · Cited by 83
Zhang, H., Huang, Y., Suvarna, N. U., Deng, C., Crissman, A. M., Hopper, A. T., Vivo, M. D., Rose, G. M., & O’Donnell, J. M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2085-2 · Cited by 81
Zhao, Z., Wang, Z., Gu, Y., Feil, R., Hofmann, F. B., & Ma, L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3770-08.2009 · Cited by 80
Patil, C. S., Singh, V. P., & Kulkarni, S. K. (2006) · PubMed · Cited by 79
Lysiak, J. J., Yang, S., Klausner, A. P., Son, H., Tuttle, J. B., & Steers, W. D. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.09.021 · Cited by 79
Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats
Rodefer, J. S., Saland, S. K., & Eckrich, S. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.008 · Cited by 75
Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspects
Kulkarni, S. K., & Patil, C. S. (2004) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2004.26.10.872561 · Cited by 70
PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury
Paterniti, I., Mazzon, E., Gil, C., Impellizzeri, D., Palomo, V., Redondo, M., Pérez, D. I., Esposito, E., Martínez, A., & Cuzzocrea, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015937 · Cited by 70
Egawa, T., Mishima, K., Matsumoto, Y., Iwasaki, K., Iwasaki, K., & Fujiwara, M. (1997) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.75.275 · Cited by 67
Reneerkens, O. A. H., Rutten, K., Akkerman, S., Blokland, A., Shaffer, C. L., Menniti, F. S., Steinbusch, H. W. M., & Prickaerts, J. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2012.02.008 · Cited by 67
Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Schmidt, C. J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411009 · Cited by 65
Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum.
Polli, J. W., & Kincaid, R. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.11079 · Cited by 64
Selective Phosphodiesterase (PDE)-4 Inhibitors: A Novel Approach to Treating Memory Deficit?
Ghavami, A., Hirst, W. D., & Novak, T. J. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00001 · Cited by 63
Medina, A. E., Krahe, T. E., & Ramoa, A. S. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4177-05.2006 · Cited by 63
van Donkelaar, E. L., Rutten, K., Blokland, A., Akkerman, S., Steinbusch, H. W. M., & Prickaerts, J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.027 · Cited by 62
Rutten, K., Wallace, T. L., Works, M. G., Prickaerts, J., Blokland, A., Novak, T. J., Santarelli, L., & Misner, D. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.020 · Cited by 56
Vinpocetine enhances retrieval of a step-through passive avoidance response in rats
DeNoble, V. J. (1987) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(87)90552-1 · Cited by 54
The Safety and Lack of Efficacy of Vinpocetine in Alzheimer's Disease
Thal, L. J., Salmon, D. P., Lasker, B. R., et al. (1989) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1989.tb05682.x · Cited by 54
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
Shindel, A. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s9067 · Cited by 54
Vardigan, J. D., Converso, A., Hutson, P. H., & Uslaner, J. M. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.630494 · Cited by 53
McPhee, I., Cochran, S. M., & Houslay, M. D. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(01)00217-0 · Cited by 49
Liebenberg, N., Harvey, B. H., Brand, L., Wegener, G., & Brink, C. B. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9284-z · Cited by 48
O'Connor, V. M., Génin, A., Davis, S., Karishma, K. K., Doyère, V., Zeeuw, C. I. D., Sanger, G. J., Hunt, S. P., Richter‐Levin, G., Mallet, J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312500200 · Cited by 45
Gallant, M., Aspiotis, R., Day, S., Dias, R., Dubé, D., Dubé, L., Friesen, R. W., Girard, M., Guay, D., Hamel, P., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.087 · Cited by 45
Boccia, M. M., Blake, M. G., Krawczyk, M. C., & Baratti, C. M. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.02.016 · Cited by 45
Changes in PDE4D Isoforms in the Hippocampus of a Patient With Advanced Alzheimer Disease
McLachlan, C. S., Chen, M. L., Lynex, C. N., Goh, D. L. M., Brenner, S., & Tay, S. K. H. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.456 · Cited by 43
Bruno, O., Romussi, A., Spallarossa, A., Brullo, C., Schenone, S., Bondavalli, F., Vanthuyne, N., & Roussel, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900977c · Cited by 43
A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition
Fusco, F., Razzoli, E., Imbimbo, C., Rossi, A., Verze, P., & Mirone, V. G. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09244.x · Cited by 40
Shim, Y. S., Pae, C.-U., Kim, S. W., Kim, H. W., Kim, J. C., & Koh, J. S. (2011) · International Journal of Impotence Research · doi:10.1038/ijir.2011.13 · Cited by 40
Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig
Kruuse, C. R., Khurana, T. S., Rybalkin, S. D., Birk, S., Engel, U., Edvinsson, L. I., & Olesen, J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.07.017 · Cited by 40
Ran, I., Laplante, I., & Lacaille, J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5463-11.2012 · Cited by 39
Krahe, T. E., Wang, W., & Medina, A. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006643 · Cited by 38
Cho, C.-H., Cho, D.-H., Seo, M., & Juhnn, Y. (2000) · Experimental & Molecular Medicine · doi:10.1038/emm.2000.19 · Cited by 38
Hosseini-Sharifabad, A., Ghahremani, M. H., Sabzevari, O., Naghdi, N., Abdollahi, M. R., Beyer, C., Bollen, E., Prickaerts, J., Roghani, A., & Sharifzadeh, M. S. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.017 · Cited by 37
Ahmad, N., Wang, Y., Ali, A. K., & Ashraf, M. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00169.2009 · Cited by 35
Cerebral Haemodynamic Response or Excitability is not Affected by Sildenafil
Kruuse, C. R., Hansen, A. E., Larsson, H. B. W., Lauritzen, M., & Rostrup, E. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.10 · Cited by 32
Molnár, P., & Gaál, L. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90602-z · Cited by 31
Lorberboym, M., Mena, I. G., Wainstein, J., Boaz, M., & Lampl, Y. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01307.x · Cited by 28
Nicholas, T., Evans, R. M., Styren, S. D., Qiu, R., Wang, E. Q., Nelson, F., Le, V., Grimwood, S., Christoffersen, C. L., Banerjee, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.553 · Cited by 25
Fujita, M., Imaizumi, M., D'Sa, C. M., Zoghbi, S. S., Crescenzo, M. S., Hong, J. S., Musachio, J. L., Gee, A. D., Seidel, J., Green, M. V., et al. (2006) · Synapse · doi:10.1002/syn.20347 · Cited by 23
Normal functional imaging of the basal ganglia
Lehéricy, S., & Gérardin, E. (2002) · Epileptic Disorders · doi:10.1684/j.1950-6945.2002.tb00543.x · Cited by 21
Sahu, M., Litvin, D. G., & Sahu, A. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.09.068 · Cited by 15
P2‐239: Cell‐based ciliary neurotrophic factor therapy against Alzheimer's disease
Garcia, P., Youssef, I., Utvik, J. K., Florent‐Béchard, S., Kriem, B., Oster, T., Niclou, S. P., & Pillot, T. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.552 · Cited by 6
Cited by
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
Salehi, B., Berkay Yılmaz, Y., Antika, G., Boyunegmez Tumer, T., Fawzi Mahomoodally, M., Lobine, D., Akram, M., Riaz, M., Capanoglu, E., Sharopov, F., et al. (2019) · Biomolecules · doi:10.3390/biom9080356 · Cited by 416
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Metadata
- Authors
- García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarzábal, J., & Franco, R.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-10-10
- Volume
- 3
- Issue
- 11
- Pages
- 832-844
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2196088104
- Cited by
- 259
- References
- 143
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.